ICAM-1 as a molecular target for triple negative breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 41, 2014, Pages 14710-14715

  Guo, Peng ^a,b,c   Huang, Jing ^d,e   Wang, Liya ^d,e   Jia, Di ^b,c   Yang, Jiang ^b,c   Dillon, Deborah A ^f   Zurakowski, David ^b   Mao, Hui ^d,e   Moses, Marsha A ^b,c   Auguste, Debra T ^a,b,c   Langer, Robert ^g  

^a City University of New York   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Department of Radiology and Imaging Sciences ^*  (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC ION; FERRIC OXIDE; INTERCELLULAR ADHESION MOLECULE 1; NANOPARTICLE; TUMOR MARKER;

ANIMAL; CHEMISTRY; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; FERRIC COMPOUNDS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MAGNETIC RESONANCE IMAGING; MICE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907921198     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1408556111     Document Type: Article

References (36)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
2. Ovcaricek T, Frkovic S, Matos E, Mozina B, Borstnar S (2011) Triple negative breast cancer-prognostic factors and survival. Radiol Oncol 45(1):46-52.
3. Slamon D, et al.; Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273-1283.
4. Yu K-D, Wu J, Shen Z-Z, Shao Z-M (2012) Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: Implication for extended endocrine therapy. J Clin Endocrinol Metab 97(12):E2201-E2209.
5. Bilici A, Arslan C, Altundag K (2012) Promising therapeutic options in triple-negative breast cancer. J BUON 17(2):209-222.
6. Gucalp A, Traina TA (2011) Triple-negative breast cancer: Adjuvant therapeutic options. Chemother Res Pract 2011:696208.
7. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8(3):235-244.
8. Carey LA, et al. (2012) TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21): 2615-2623.
9. Cristofanilli M, et al. (2008) Imatinib mesylate (Gleevec) in advanced breast cancerexpressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. Ann Oncol 19(10):1713-1719.
10. O'Shaughnessy J, et al. (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205-214.
11. Modi S, et al. (2005) A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 90(2):157-163.
12. Baselga J, et al. (2013) Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 31(20):2586-2592.
13. Liu JF, et al. (2013) A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49(14): 2972-2978.
14. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7(2):79-94.
15. Müller A, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56.
16. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271-285.
17. Xia M, Sui Z (2009) Recent developments in CCR2 antagonists. Expert Opin Ther Pat 19(3):295-303.
18. Chui R, Dorovini-Zis K (2010) Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J Neuroinflammation 7:1.
19. Hayes SH, Seigel GM (2009) Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol 2(6):553-560.
20. Roland CL, Harken AH, Sarr MG, Barnett CC Jr (2007) ICAM-1 expression determines malignant potential of cancer. Surgery 141(6):705-707.
21. Rosette C, et al. (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26(5):943-950.
22. Huang J, et al. (2013) Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. ACS Appl Mater Interfaces 5(11):4632-4639.
23. Chen T-J, et al. (2009) Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 14(2):253-260.
24. Huh Y-M, et al. (2005) In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 127(35):12387-12391.
25. Burns RC, et al. (2001) Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121(6):1428-1436.
26. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ (2002) Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22(2):146-167.
27. Veitonmäki N, et al. (2013) A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 23(4):502-515.
28. Lawson C, Wolf S (2009) ICAM-1 signaling in endothelial cells. Pharmacol Rep 61(1): 22-32.
29. Mileski WJ, et al. (2003) Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. J Trauma 54(5):950-958.
30. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE (1997) Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 40(5):849-853.
31. Schneider D, et al. (1998) Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): An open-label, dose escalation study in patients hospitalized for acute stroke. Eur Neurol 40(2):78-83.
32. Greenwood J, et al. (2003) Intracellular domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-mediated signaling and migration. J Immunol 171(4):2099-2108.
33. Yang J, et al. (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 106(10):3913-3918.
34. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279(49):51323-51330.
35. Guo P, et al. (2014) Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm 11(3):755-765.
36. Guo P, You J-O, Yang J, Moses MA, Auguste DT (2012) Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials 33(32): 8104-8110.